Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence.

[1]  G. Ruoppolo,et al.  Kawasaki disease: an evolving paradigm. , 2015, Autoimmunity reviews.

[2]  G. Zandman-Goddard,et al.  The role of intravenous immunoglobulins in the treatment of rheumatoid arthritis. , 2015, Autoimmunity reviews.

[3]  A. Fioravanti,et al.  Granulomatosis with polyangiitis and intravenous immunoglobulins: a case series and review of the literature. , 2015, Autoimmunity reviews.

[4]  S. Spector,et al.  Practice parameter for the diagnosis and management of primary immunodeficiency. , 2015, The Journal of allergy and clinical immunology.

[5]  T. Kuijpers,et al.  On the Dark Side of Therapies with Immunoglobulin Concentrates: The Adverse Events , 2015, Front. Immunol..

[6]  B. Costa-Carvalho,et al.  Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions. , 2014, International immunopharmacology.

[7]  A. Gabrielli,et al.  Subcutaneous IgG in immune-mediate diseases: proposed mechanisms of action and literature review. , 2014, Autoimmunity reviews.

[8]  D. Zillikens,et al.  Eczematous reaction to intravenous immunoglobulin: an alternative cause of eczema. , 2014, JAMA dermatology.

[9]  T. Burnouf,et al.  Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products. , 2014, Biologicals : journal of the International Association of Biological Standardization.

[10]  E. Herzog,et al.  Assessment of the ability of the Privigen® purification process to deplete thrombogenic factor XIa from plasma , 2014, Vox sanguinis.

[11]  A. Borobia,et al.  Symptomatic thromboembolic events in patients treated with intravenous-immunoglobulins: results from a retrospective cohort study. , 2014, Thrombosis research.

[12]  J. Franco,et al.  Guidelines for the use of human immunoglobulin therapy in patients with primary immunodeficiencies in Latin America. , 2014, Allergologia et immunopathologia.

[13]  K. Johnston,et al.  Current perspectives on the use of intravenous recombinant tissue plasminogen activator (tPA) for treatment of acute ischemic stroke , 2014, Vascular health and risk management.

[14]  S. L. Kwong,et al.  Adverse events of intravenous immunoglobulin infusions: a ten-year retrospective study , 2013, Asia Pacific allergy.

[15]  J. Dantal.  Intravenous Immunoglobulins: In-Depth Review of Excipients and Acute Kidney Injury Risk , 2013, American Journal of Nephrology.

[16]  K. Hanschmann,et al.  Thromboembolic events associated with immunoglobulin treatment , 2013, Vox sanguinis.

[17]  E. R. Stiehm,et al.  Adverse effects of human immunoglobulin therapy. , 2013, Transfusion medicine reviews.

[18]  L. Mouthon,et al.  In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations , 2013, Vox sanguinis.

[19]  David C. Martin,et al.  Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010 , 2012, Transfusion.

[20]  H. Ochs,et al.  Home-Based Subcutaneous Immunoglobulin Versus Hospital-Based Intravenous Immunoglobulin in Treatment of Primary Antibody Deficiencies: Systematic Review and Meta Analysis , 2012, Journal of Clinical Immunology.

[21]  P. Bentley,et al.  Intravenous immunoglobulin increases plasma viscosity without parallel rise in blood pressure , 2012, Journal of clinical pharmacy and therapeutics.

[22]  R. Scuccimarri,et al.  Hemolytic anemia following intravenous immunoglobulin therapy in patients treated for Kawasaki disease: a report of 4 cases , 2012, Pediatric Rheumatology.

[23]  J. Dodt,et al.  Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products , 2012, Vox sanguinis.

[24]  P. Cherin,et al.  Relevant Criteria for Selecting an Intravenous Immunoglobulin Preparation for Clinical Use , 2010, BioDrugs.

[25]  Y. Rajabally,et al.  Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: A two-year study , 2011, Journal of the Neurological Sciences.

[26]  T. Saji,et al.  Clinical characteristics of aseptic meningitis induced by intravenous immunoglobulin in patients with Kawasaki disease , 2011, Pediatric rheumatology online journal.

[27]  Hafiz M. R. Khan,et al.  The Safety Profile of Home Infusion of Intravenous Immunoglobulin in Patients With Neuroimmunologic Disorders , 2011, Journal of clinical neuromuscular disease.

[28]  W. Sewell,et al.  Serum trough IgG level and annual intravenous immunoglobulin dose are not related to body size in patients on regular replacement therapy. , 2011, Drug metabolism letters.

[29]  J. Kanellis,et al.  Slow and steady. Reducing thrombotic events in renal transplant recipients treated with IVIg for antibody‐mediated rejection , 2011, Nephrology.

[30]  G. Verleden,et al.  REPEATED, SEVERE HEADACHE IN A LUNG TRANSPLANT PATIENT : A CASE REPORT , 2010, Acta clinica Belgica.

[31]  D. Keskin,et al.  Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products. , 2010, Autoimmunity reviews.

[32]  Kathleen C. Williams,et al.  Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. , 2010, Clinical immunology.

[33]  S. Jordan,et al.  Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[34]  H. Ochs,et al.  Subcutaneous immunoglobulin: opportunities and outlook , 2009, Clinical and experimental immunology.

[35]  S. Miescher,et al.  In vitro comparison of the complement‐scavenging capacity of different intravenous immunoglobulin preparations , 2009, Vox sanguinis.

[36]  S. Fedele,et al.  Analysis of thromboembolic risk related to high‐dose intravenous immunoglobulin treatment: a preliminary clinical study of 10 patients with autoimmune mucocutaneous blistering diseases , 2009, Clinical and experimental dermatology.

[37]  L. Hobson‐Webb,et al.  Case-control study of thromboembolic events associated with IV immunoglobulin , 2009, Journal of Neurology.

[38]  N. Pouladi,et al.  Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases. , 2009, Journal of investigational allergology & clinical immunology.

[39]  M. Eibl.  History of immunoglobulin replacement. , 2008, Immunology and allergy clinics of North America.

[40]  J. Hooper.  Intravenous Immunoglobulins: Evolution of Commercial IVIG Preparations , 2008, Immunology and Allergy Clinics of North America.

[41]  R. Padmore,et al.  Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis , 2008, Transfusion.

[42]  B. Wolach,et al.  Transfusion‐related acute lung injury following intravenous anti‐D administration in an adolescent , 2008, American journal of hematology.

[43]  A. Alangari,et al.  Intravenous immunoglobulin utilization in a tertiary care teaching hospital in Saudi Arabia. , 2008, Saudi medical journal.

[44]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[45]  M. Longy-Boursier,et al.  Effets indésirables liés aux immunoglobulines humaines normales: intérêt des mesures de prévention. , 2008 .

[46]  H. Gürcan,et al.  Frequency of Adverse Events Associated with Intravenous Immunoglobulin Therapy in Patients with Pemphigus or Pemphigoid , 2007, The Annals of pharmacotherapy.

[47]  A. Fasth,et al.  Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency , 2007, Acta paediatrica.

[48]  K. Stylianou,et al.  Acute Renal Failure, Translocational Hyponatremia and Hyperkalemia following Intravenous Immunoglobulin Therapy , 2007, Nephron Clinical Practice.

[49]  M. Ballow.  Safety of IGIV therapy and infusion-related adverse events , 2007, Immunologic research.

[50]  F. Fakhouri.  [Intravenous immunoglobulins and acute renal failure: mechanism and prevention]. , 2007, La Revue de medecine interne.

[51]  R. Sorensen.  Expert Opinion Regarding Clinical and Other Outcome Considerations in the Formulary Review of Immune Globulin , 2007, Journal of managed care pharmacy : JMCP.

[52]  F. Fakhouri.  Immunoglobulines intraveineuses et insuffisance rénale : mécanisme et prévention , 2007 .

[53]  S. Fedele,et al.  Variations in Serum Hemoglobin, Albumin, and Electrolytes in Patients Receiving Intravenous Immunoglobulin Therapy , 2007, American journal of clinical dermatology.

[54]  S. Miescher,et al.  Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. , 2006, Blood.

[55]  F. Haramburu,et al.  Tolérance des immunoglobulines polyvalentes, impact de l'utilisation d'un protocole de prescription sur la survenue d'effets indésirables liés au traitement , 2006 .

[56]  I. Marie,et al.  Intravenous immunoglobulin-associated vena cava thrombosis , 2006, Thrombosis and Haemostasis.

[57]  I. Marie,et al.  Intravenous immunoglobulin‐associated arterial and venous thrombosis; report of a series and review of the literature , 2006, The British journal of dermatology.

[58]  S. Jordan,et al.  Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: a single-center experience. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[59]  H. Ochs,et al.  Safety and Efficacy of Self-Administered Subcutaneous Immunoglobulin in Patients with Primary Immunodeficiency Diseases , 2006, Journal of Clinical Immunology.

[60]  A. Rastogi,et al.  True hyponatremia secondary to intravenous immunoglobulin , 2006, Clinical and Experimental Nephrology.

[61]  B. Reid,et al.  Protocol Recommendations for Administration of Intravenous Immunoglobulin in Canada , 2006, Journal of infusion nursing : the official publication of the Infusion Nurses Society.

[62]  Ó. Asensio,et al.  Rapid Subcutaneous IgG Replacement Therapy is Effective and Safe in Children and Adults with Primary Immunodeficiencies—A Prospective, Multi-National Study , 2006, Journal of Clinical Immunology.

[63]  D. Singh-Grewal,et al.  A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusions , 2006, Archives of Disease in Childhood.

[64]  D. Hamrock,et al.  Adverse events associated with intravenous immunoglobulin therapy. , 2006, International immunopharmacology.

[65]  J. Orange,et al.  Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. , 2006, The Journal of allergy and clinical immunology.

[66]  J. Siegel.  Safety considerations in IGIV utilization. , 2006, International immunopharmacology.

[67]  A. Achiron,et al.  Long term safety of IVIg therapy in multiple sclerosis: 10 years experience , 2006, Autoimmunity.

[68]  Y. Shoenfeld,et al.  Intravenous immunoglobulin , 2005, Clinical reviews in allergy & immunology.

[69]  J. Siegel.  The Product: All Intravenous Immunoglobulins Are Not Equivalent , 2005, Pharmacotherapy.

[70]  M. Borte,et al.  [Treatment of patients with primary antibody deficiencies in Germany]. , 2005, Klinische Padiatrie.

[71]  R. Ben-Ami,et al.  Venous and arterial thrombosis following administration of intravenous immunoglobulins , 2005 .

[72]  T. Trujillo,et al.  Intravenous Immunoglobulin–Associated Acute Renal Failure: Case Series and Literature Review , 2005, Pharmacotherapy.

[73]  V. Moalic,et al.  Syndrome de détresse respiratoire aiguë post-transfusionnel : une pathologie méconnue , 2005 .

[74]  L. Raffini,et al.  Neutropenia Following IVIG Therapy in Pediatric Patients With Immune-Mediated Thrombocytopenia , 2005, Journal of pediatric hematology/oncology.

[75]  C. Férec,et al.  [Transfusion related acute lung injury (TRALI): an unrecognised pathology]. , 2005, Pathologie-biologie.

[76]  Y. Shoenfeld,et al.  Intravenous immunoglobulin and the kidney--a two-edged sword. , 2004, Seminars in arthritis and rheumatism.

[77]  S. Chapman,et al.  Acute Renal Failure and Intravenous Immune Globulin: Occurs with Sucrose-Stabilized, but Not with D-Sorbitol–Stabilized, Formulation , 2004, The Annals of pharmacotherapy.

[78]  Ó. Asensio,et al.  Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. , 2004, The Journal of allergy and clinical immunology.

[79]  C. Pozzilli,et al.  Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial , 2004, The Lancet.

[80]  M. Aihara,et al.  An infant with γ-globulin-induced hypersensitivity syndrome who developed Evans' syndrome after a second γ-globulin treatment , 2004, Modern rheumatology.

[81]  F. Bonilla.  PROSPECTIVE AUDIT OF ADVERSE REACTIONS OCCURRING IN 459 PRIMARY ANTIBODY-DEFICIENT PATIENTS RECEIVING INTRAVENOUS IMMUNOGLOBULIN , 2004, Pediatrics.

[82]  M. Berger.  Subcutaneous immunoglobulin replacement in primary immunodeficiencies. , 2004, Clinical immunology.

[83]  M. Dalakas,et al.  The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. , 2004, Pharmacology & therapeutics.

[84]  J. Sinclair,et al.  Increased risk of adverse events when changing intravenous immunoglobulin preparations , 2004, Clinical and experimental immunology.

[85]  D. Ericson,et al.  The Comparison of the Efficacy and Safety of Intravenous Versus Subcutaneous Immunoglobulin Replacement Therapy , 2000, Journal of Clinical Immunology.

[86]  Y. Shoenfeld,et al.  Anti-DNA and Antiphospholipid Antibodies in IVIG Preparations: In Vivo Study in Naive Mice , 2004, Journal of Clinical Immunology.

[87]  T. Hashimoto,et al.  Neutropenia as a Complication of High-Dose Intravenous Immunoglobulin Therapy in Adult Patients With Neuroimmunologic Disorders , 2003, Clinical neuropharmacology.

[88]  R. Geha,et al.  The X-Linked Hyper-IgM Syndrome: Clinical and Immunologic Features of 79 Patients , 2003, Medicine.

[89]  N. Jain,et al.  Risks associated with the use of intravenous immunoglobulin. , 2003, Transfusion medicine reviews.

[90]  M. Kruskall,et al.  Intravenous immune globulins: an update for clinicians , 2003, Transfusion.

[91]  M. Dalakas,et al.  Strokes, thromboembolic events, and IVIg , 2003, Neurology.

[92]  M. Cartwright,et al.  The clinical features of 16 cases of stroke associated with administration of IVIg , 2003, Neurology.

[93]  D. Okuda,et al.  Arterial thrombosis induced by IVIg and its treatment with tPA , 2003, Neurology.

[94]  S. Ford,et al.  Intravenous immunoglobulin therapy results in post‐infusional hyperproteinemia, increased serum viscosity, and pseudohyponatremia , 2003, American journal of hematology.

[95]  J. V. D. van der Meer,et al.  Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy. , 2003, The Netherlands journal of medicine.

[96]  N. Evangelou,et al.  Transverse sinus thrombosis and IVIg treatment: a case report and discussion of risk–benefit assessment for immunoglobulin treatment , 2003, Journal of clinical pathology.

[97]  P. Korenblat,et al.  A randomized double-blind trial , 2003 .

[98]  T. Brannagan.  Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies , 2002, Neurology.

[99]  C. Cunningham-Rundles,et al.  Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. , 2002, The Journal of allergy and clinical immunology.

[100]  R. Hughes,et al.  Intravenous immunoglobulin in neurological disease: a specialist review , 2002, Journal of neurology, neurosurgery, and psychiatry.

[101]  L. Watson,et al.  Intravenous Immunoglobulin-Related Acute Coronary Syndrome and Coronary Angiography in Idiopathic Thrombocytopenic Purpura , 2002, Angiology.

[102]  C. Cunningham-Rundles,et al.  Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency. , 2001, Clinical immunology.

[103]  J. Lewis,et al.  Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders , 2001, Neurology.

[104]  G. Comi,et al.  Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy , 2001, Annals of neurology.

[105]  L. Rauova,et al.  Adverse Effects of Intravenous Immunoglobulin Therapy in 56 Patients with Autoimmune Diseases , 2001, Pharmacology.

[106]  R. Weinstein,et al.  Transfusion‐related acute lung injury after the infusion of IVIG , 2001, Transfusion.

[107]  J. Levy,et al.  Nephrotoxicity of intravenous immunoglobulin. , 2000, QJM : monthly journal of the Association of Physicians.

[108]  A. Wolberg,et al.  Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations , 2000, American journal of hematology.

[109]  Epstein Js,et al.  Important drug warning: Immune Globulin Intravenous (human) (IGIV) products. , 2000 .

[110]  T. Taga,et al.  Severe hemolytic anemia following high‐dose intravenous immunoglobulin administration in a patient with Kawasaki Disease , 2000, American journal of hematology.

[111]  W. Sewell,et al.  Drug-Induced Aseptic Meningitis , 2000, Drug safety.

[112]  M. Yaron,et al.  Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases , 2000, Annals of the rheumatic diseases.

[113]  K. Zoon,et al.  Important drug warning: Immune Globulin Intravenous (human) (IGIV) products. , 2000, Neonatal network : NN.

[114]  M. Dalakas.  Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines. , 1999, Muscle & nerve.

[115]  M. Sturzenegger,et al.  Adverse Effects of Intravenous Immunoglobulin Therapy , 1999, Drug safety.

[116]  S. Ng.  Intravenous immunoglobulin infusion causing pseudohyponatremia , 1999, Lupus.

[117]  C. Cunningham-Rundles,et al.  Common variable immunodeficiency: clinical and immunological features of 248 patients. , 1999, Clinical immunology.

[118]  P G Shekelle,et al.  Developing clinical guidelines. , 1999, The Western journal of medicine.

[119]  M. Berkovitch,et al.  Neutropenia as a complication of intravenous immunoglobulin (IVIG) therapy in children with immune thrombocytopenic purpura: common and non-alarming. , 1999, International journal of immunopharmacology.

[120]  P. Eggimann,et al.  High-Dose Intravenous Immunoglobulin Treatment and Cerebral Vasospasm: A Possible Mechanism of Ischemic Encephalopathy? , 1999, European Neurology.

[121]  E. Wegmüller.  Effect of intravenous immunoglobulin therapy on plasma complement. , 1998, Transfusion science.

[122]  Fontana,et al.  High‐Dose Intravenous Immunoglobulin Treatment Activates Complement In Vivo , 1998, Scandinavian journal of immunology.

[123]  J. Muir,et al.  Une cause rare d'hémorragie intra-alvéolaire: l'accident transfusionnel avec leucoagglutination par anticorps antigranuleux (syndrome Trali) , 1998 .

[124]  A. Cuvelier,et al.  [A rare cause of intra-alveolar hemorrhage: a transfusion-related incident with leukoagglutination due to antigranulocyte antibodies (Trali syndrome)]. , 1998, La Revue de medecine interne.

[125]  J. Howard,et al.  Successful Treatment of Headache Related to Intravenous Immunoglobulin With Antimigraine Medications , 1998, Headache.

[126]  R. Mamidi,et al.  IVIG Adverse Reactions: Potential Role of Cytokines and Vasoactive Substances , 1998, Vox Sanguinis.

[127]  H. Hartung,et al.  Intravenous immunoglobulin treatment of neurological autoimmune diseases , 1998, Journal of the Neurological Sciences.

[128]  A. Achiron.  Complications of intravenous immune globulin treatment in neurologic disease , 1997, Neurology.

[129]  John R. Wilson,et al.  Hemolytic anemia associated with intravenous immunoglobulin , 1997, Muscle & nerve.

[130]  M. Dalakas.  Intravenous Immune Globulin Therapy for Neurologic Diseases , 1997, Annals of Internal Medicine.

[131]  W. Hacke,et al.  Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome , 1997 .

[132]  U. Nydegger.  Safety and side effects of i.v. immunoglobulin therapy. , 1996, Clinical and experimental rheumatology.

[133]  D. Stroncek,et al.  Neutropenia in a patient receiving intravenous immune globulin , 1996, Journal of Neuroimmunology.

[134]  T. Yousry,et al.  Reversible encephalopathy with cerebral vasospasm in a Guillain-Barre syndrome patient treated with intravenous immunoglobulin , 1996, Neurology.

[135]  T. Ratko,et al.  Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations. , 1995, JAMA.

[136]  M. Dalakas.  Aseptic Meningitis and Intravenous Immunoglobulin Therapy , 1995, Annals of Internal Medicine.

[137]  R. I. Schiff.  Transmission of viral infections through intravenous immune globulin. , 1994, The New England journal of medicine.

[138]  N. Liabakk,et al.  Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. , 1994, Blood.

[139]  M. Dalakas,et al.  Aseptic Meningitis Associated with High-Dose Intravenous Immunoglobulin Therapy: Frequency and Risk Factors , 1994, Annals of Internal Medicine.

[140]  C. Duhem,et al.  Side-effects of intravenous immune globulins. , 1994, Clinical and experimental immunology.

[141]  M. Swenson,et al.  Aseptic meningitis as a complication of intravenous immunoglobulin therapy for myasthenia gravis , 1994, Muscle & nerve.

[142]  M. Dalakas.  High‐dose intravenous immunoglobulin and serum viscosity , 1994, Neurology.

[143]  F. Retornaz,et al.  Deleterious effects of intravenous immunoglobulin in a patient with thrombotic thrombocytopenic purpura , 1993, American journal of hematology.

[144]  L. McCluskey,et al.  Recurrent migraine and intravenous immune globulin therapy. , 1993, The New England journal of medicine.

[145]  Z. Meiner,et al.  Aseptic meningitis as complication of intravenous immunoglobulin therapy for myasthenia gravis. , 1993, Journal of neurology, neurosurgery, and psychiatry.

[146]  P. Cherin,et al.  Ischemic Vernet's syndrome in giant cell arteritis: first two cases. , 1992, The American journal of medicine.

[147]  W. Reinhart,et al.  Effect of high-dose intravenous immunoglobulin therapy on blood rheology , 1992, The Lancet.

[148]  S. Miller,et al.  Intravenous immune globulin and aseptic meningitis. , 1992, American journal of diseases of children.

[149]  J. Dwyer.  Manipulating the immune system with immune globulin. , 1992, The New England journal of medicine.

[150]  J. Piette,et al.  Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. , 1991, The American journal of medicine.

[151]  L. Mofenson,et al.  Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. , 1991, The New England journal of medicine.

[152]  R. Buckley,et al.  The use of intravenous immune globulin in immunodeficiency diseases. , 1991, The New England journal of medicine.

[153]  U. Nydegger,et al.  Defining the Specificity of Anti‐A/B IgM/G Antibodies with Different Antigens and Lectins 1 , 1991, Vox sanguinis.

[154]  Intravenous immunoglobulin: prevention and treatment of disease. Summary of the NIH Consensus Development Conference. , 1991, Transfusion medicine reviews.

[155]  B. Wechsler,et al.  Intravenous immunoglobulin for polymyositis and dermatomyositis , 1990, The Lancet.

[156]  S. Okubo,et al.  Hemolysis after intravenous immune globulin therapy: relation to IgG subclasses of red cell antibody , 1990, Transfusion.

[157]  A. Randomized.  Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. , 1988 .

[158]  C. Hosking,et al.  Use of methylprednisolone as prophylaxis for immediate adverse infusion reactions in hypogammaglobulinaemic patients receiving intravenous immunoglobulin: A controlled trial , 1988, Australian paediatric journal.

[159]  G. Herrera,et al.  Acute cryoglobulinemic renal failure after intravenous infusion of gamma globulin. , 1987, The American journal of medicine.

[160]  A. Grigg,et al.  FATAL THROMBOTIC EVENTS DURING TREATMENT OF AUTOIMMUNE THROMBOCYTOPENIA WITH INTRAVENOUS IMMUNOGLOBULIN IN ELDERLY PATIENTS , 1986, The Lancet.

[161]  A. Burks,et al.  Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. , 1986, The New England journal of medicine.

[162]  H. Levison,et al.  Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease. , 1985, The American journal of medicine.

[163]  J. Winkelstein,et al.  X‐Linked Agammaglobulinemia: An Analysis of 96 Patients , 1985, Medicine.

[164]  Katsuko Sato,et al.  HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR KAWASAKI DISEASE , 1983, The Lancet.

[165]  H. Ochs,et al.  Use of intravenous gamma-globulin in antibody immunodeficiency: results of a multicenter controlled trial. , 1982, Clinical immunology and immunopathology.

[166]  A. Hirt,et al.  HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDHOOD , 1981, The Lancet.